Efficacy and safety of denosumab, zoledronic acid and alendronate on bone mineral density and trabecular bone score in men with osteoporosis
Age and Ageing · 04.05.2026 · 55 (5)
DOI: 10.1093/ageing/afag121 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Age and Ageing, online erschienen am 07.05.2026. Verfasst von Bingna Zhou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, …. Hauptthemen laut MEDLINE: Denosumab, Zoledronic Acid, Bone Density, Osteoporosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Objective
Osteoporosis in men is a common but often neglected health problem. We aim to compare the efficacy and safety of denosumab, zoledronic acid and alendronate in men with osteoporosis.
Methods
In this randomized, comparative, open-label study, 390 men with osteoporosis or osteopenia were included. They were randomized to receive the treatment of denosumab, alendronate, or zoledronic acid for 12 months. The percentage changes in bone mineral density (BMD), trabecular bone score (TBS) and bone turnover biomarkers (BTMs) during the treatment were evaluated. Safety parameters were observed.
Results
The baseline characteristics were well balanced among the three groups. After 12 months of treatment, denosumab, alendronate and zoledronic acid significantly increased BMD by 4.83 ± 0.89%, 4.32 ± 0.77%, 5.18 ± 0.73% at lumbar spine, by 2.75 ± 0.51%, 2.50 ± 0.61% and 2.83 ± 0.59% at total hip, TBS was significantly increased by 2.44 ± 0.52%, 2.00 ± 0.64%, 2.29 ± 0.55%, respectively, without significant differences among the three groups. Serum levels of BTMs decreased significantly and similarly in all three groups (all P < .05 vs. baseline). Denosumab and alendronate group had fewer adverse events than zoledronic acid group. Denosumab had similar efficacy in patients with different gonadal functions. In patients previously receiving bone resorption inhibitors, denosumab continued to increase BMD and TBS, but the increments were reduced by approximately 30% in BMD at lumbar spine compared with treatment-naive patients.
Conclusion
Denosumab, alendronate and zoledronic acid significantly and similarly reduced BTMs, increased BMD and TBS in men with osteoporosis, whether the gonadal function of patients was normal or decreased. Previous anti-bone resorption therapy may partially diminish the efficacy of denosumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,…
- Department of Endocrinology and Metabolism, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China.
- Department of Orthopedics, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China.
- Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China.
ORCID-Profile: Yan Jiang, Ou Wang, Weibo Xia, Weigang Yan, Mei Li
Förderung
- National Natural Science Foundation of China
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Zhou, B., Zhang, Y., Yu, W., Sun, L., Wang, Y., Jiang, Y., Wang, O., Xing, X., Xia, W., Zhang, J., Yan, W., & Li, M. (2026). Efficacy and safety of denosumab, zoledronic acid and alendronate on bone mineral density and trabecular bone score in men with osteoporosis. Age and Ageing, 55(5). https://doi.org/10.1093/ageing/afag121
Vancouver
Zhou B, Zhang Y, Yu W, Sun L, Wang Y, Jiang Y, et al. Efficacy and safety of denosumab, zoledronic acid and alendronate on bone mineral density and trabecular bone score in men with osteoporosis. Age and Ageing. 2026;55(5). doi:10.1093/ageing/afag121
BibTeX
@article{Zhou2026,
author = {Zhou, Bingna and Zhang, Yi and Yu, Wei and Sun, Lei and Wang, Yanye and Jiang, Yan and Wang, Ou and Xing, Xiaoping and Xia, Weibo and Zhang, Jia and Yan, Weigang and Li, Mei},
title = {Efficacy and safety of denosumab, zoledronic acid and alendronate on bone mineral density and trabecular bone score in men with osteoporosis},
journal = {Age and Ageing},
year = {2026},
volume = {55},
number = {5},
doi = {10.1093/ageing/afag121}
}
EUVIMED